|Mr. John Simard||Founder, Pres, CEO & Chairman||786.97k||N/A||1962|
|Ms. Queena Han B.A., CPA, C.G.A.||VP of Fin. & HR and Sec.||198.95k||N/A||1967|
|Dr. Sushma Shivaswamy||Chief Scientific Officer||312.48k||N/A||1978|
|Mr. Benjamín Guzmán||Sr. VP of Corp. Strategy & Fin.||N/A||N/A||1956|
|Dr. William Levis||Interim Medical Director and Member of Scientific Advisory Board||N/A||N/A||N/A|
XBiotech Inc., a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection and influenza diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.
XBiotech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.